logo_desma

About Us

An international pharmaceutical group with 90 years of experience and a recent history of prestigious acquisitions and global expansion.

Our manufacturing plants are based in Italy along with 47 countries in Europe, in the Middle East and Far East, and South America. We distribute 73 brands directly or in a partnership with local realities, worldwide.

Our strength is our capability to combine pharmaceuticals competences with a globally strategic vision, able to create synergies to enhance international mergers and acquisitions and generate a constant growth.

We acquire and complete our quality product portfolio, by relaunching such products and extending their life cycle, along with economic benefits for our partner distributors and easy access to our products both for patients and consumers, worldwide.

Innovation, tradition and internationality

A long view into the future is constantly anchored to the values of our origin, the ones that have turned a family Italian company into a modern and international Pharmaceutical Group. Rigour and flexibility, innovation and tradition, are for us solid benchmarks that guarantee an excellent production. Our goal is to reach people with accessible and quality therapeutic solutions, in order to transfer the product’s value over time into treatments and well-being.

76,0 €

million turnover

47

countries

283

products in the world

73

brands

90

more years of exeperience

144

people employed directly

Laboratorio Farmaceutico SIT was founded.
1927
1973
Mercurocromo was acquired.
SIT provided itself with a sales force in Italy.
1987
1993
Eparema, Diube, Tauglicolo and Tauxolo were acquired.
Mercurocromo with merbromin was reformulated in SIT and relaunched as Neomercurocromo eosin based.
1994
1997
Coryfin, Priovit and Neutrolac were acquired.
Desma Swiss was founded.
1998
1999
Desma Germany was founded.
The new production plant in Mede was enaugurated.
DMS Farmaceutici was founded.
Infloran and Flexiban were acquired.
2001
2003
Desma Healthcare and Desma Spain were founded.
Rino Calyptol was acquired from Aventis Pharma Spa.
The acquisition of Dedrogyl and Sterogyl from Aventis Pharma Spa fostered the European market and gave way to the distribution in Vietnam, Tunisia and Algeria.
Desma France was founded.
The acquisition of Akineton from Abbott GmbH & Co. KG opened up new markets in Europe: Austria, Belgium, Bosnia & Herzegovina, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Norway, Holland, Poland, Portugal, Russian Federation, Slovakia, Slovenia, Spain, Sweden, Switzerland.
2004
2005
Kalinor was acquired from Abbott Gmbh & Co.KG.
Felison and Ferrofolin were acquired from Bayer Spa.
2009
2011
Control was acquired from Bayer Spa.
Centellase was acquired from Bayer Consumer Care Ag.
2012
2015
SIT provided itself with a network of medical sales reps.
Desma France provided itself with a network of medical sales reps.
2017
2018
Desma Spain has provided itself with a network of medical sales reps.
New Market Australia and Hong Kong.
2019
2020
Lopressor, Miorel and Icaz were acquired from Daiichi Sankyo France.
New markets: Africa countries.

Pharmacovigilance | Cookie | Privacy | Contacts

 

Copyright 2018 © DESMA HEALTHCARE S.p.A.
Legal head office: Via Ettore De Sonnaz, 19 – 10121 Torino
Operational headquarters Italy Via Cavour, 70 - 27035 Mede(PV)
Ph. +39 0384.807100 Fax. - +39 0384.822133
Share capital € 13.000.000,00 i.v. - VAT 06414660016 CCIAA di Torino REA n. 786296 Registro Imprese di Torino n. 349/93